CSF Phosphoproteomics Biomarker Analysis from the Phase 2 Clinical Trial SHINE to Elucidate the Role of CT1812 in Alzheimer’s Disease

Documents similaires

• TOP‐LINE CSF Biomarker Outcomes from the Phase 2 Clinical Trial SHINE in Alzheimer’s Patients
  par: Valentina Di Caro, et autres
  Publié: (2024)
• Exploratory CSF proteomics biomarker outcomes of the the phase 2 clinical trial shine to assess the effects of CT1812 in Alzheimer’s patients
  par: Valentina Di Caro, et autres
  Publié: (2024)
• Plasma proteomic analysis of a biomarker‐defined subpopulation in the SHINE Ph2 trial to identify molecular correlates to the favorable decrease in the neuroinflammatory marker GFAP with zervimesine in Alzheimer's disease participants
  par: Britney N Lizama, et autres
  Publié: (2025)
• Exploratory CSF proteomic analysis of a pre‐specified pTau217 subgroup from the SHINE clinical trial identifies biomarkers correlated with cognitive improvement in Alzheimer’s disease patients treated with zervimesine
  par: Britney N Lizama, et autres
  Publié: (2025)
• Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812
  par: Valentina Di Caro, et autres
  Publié: (2025)